{"id":296411,"date":"2023-05-11T00:00:00","date_gmt":"2023-05-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0006-2023-biopharma-multiple-sclerosis-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-05-09T11:16:11","modified_gmt":"2026-05-09T11:16:11","slug":"cutrcg0006-2023-biopharma-multiple-sclerosis-current-treatment-current-treatment-physician-insights-multiple-sclerosis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0006-2023-biopharma-multiple-sclerosis-current-treatment-current-treatment-physician-insights-multiple-sclerosis\/","title":{"rendered":"Multiple Sclerosis &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Multiple Sclerosis (US)"},"content":{"rendered":"<p>Numerous disease-modifying therapies (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s) have entered the multiple sclerosis (<abbr title=\"multiple sclerosis\">MS<\/abbr>) disease landscape in recent years, and many of them are next-generation alternatives within existing classes. Most recently, <span class=\"abbreviation-guard\">TG<\/span> Therapeutics launched Briumvi, the third-in-class anti-CD20 monoclonal antibody. Given the rapid pace of expansion in the <abbr title=\"multiple sclerosis\">MS<\/abbr> market, developers of both current and emerging <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s must continually reassess their products\u2019 differentiation and likely positioning in this highly competitive space. This report will explore neurologists\u2019 perceptions of established and recently launched <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s, their prescribing habits in today\u2019s market, and anticipated changes in brand usage as more <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s expand\u2014and further complicate\u2014prescriber choice.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How are different <abbr title=\"multiple sclerosis\">MS<\/abbr> subpopulations (i.e., clinically isolated syndrome, relapsing-remitting, secondary-progressive, and primary-progressive) treated today?<\/li>\n<li>How do product shares differ across lines of therapy? Are high-efficacy therapies (e.g., Ocrevus) factoring more into early-line treatment decisions?<\/li>\n<li>How are the <abbr title=\"sphingosine 1-phosphate\">S1P<\/abbr> receptor modulator and anti-CD20 classes changing with expansion?<\/li>\n<li>How has neurologists\u2019 prescribing changed in the past year, and why? What further changes do they expect within the next year?<\/li>\n<li>What are neurologists\u2019 opinions of the newest entrants in the <abbr title=\"multiple sclerosis\">MS<\/abbr> market, and how are they incorporating these <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s in the treatment paradigm?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><em>Current Treatment: Physician Insights<\/em> provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Primary research: <\/strong>Survey of 100 U.S. neurologists<\/p>\n<p><strong>Key drugs covered: <\/strong>Aubagio, Briumvi, glatiramer acetate, Gilenya, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera, Tysabri, Vumerity, Zeposia<\/p>\n<p><strong>Key companies: <\/strong>Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Roche, Sanofi Genzyme, <span class=\"abbreviation-guard\">TG<\/span> Therapeutics<\/p>\n<p><strong>Key insights provided: <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers and constraints of treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<li>Rationale for changes in treatment approach.<\/li>\n<li>Physician insight on persistency and compliance.<\/li>\n<li>Physician-reported recent\/anticipated changes in brand usage or treatment approach.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296411","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296411\/revisions"}],"predecessor-version":[{"id":296634,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296411\/revisions\/296634"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}